Medicare Enrolled

Dr. Mohamed Haq, MD

Hematology & Oncology · Houston, TX
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
11950 OLD GALVESTON RD, Houston, TX 77034
7139472142
In practice since 2006 (20 years)
NPI: 1326011347 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Haq from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Haq? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Haq

Dr. Mohamed Haq is a hematology & oncology specialist in Houston, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Haq performed 2,777 Medicare services across 268 unique beneficiaries.

Between the years covered by Open Payments, Dr. Haq received a total of $9,560 from 48 pharmaceutical and/or device companies across 306 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Haq is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 42% volume in TX $9,560 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,777
Medicare services
Top 42% in TX for hematology & oncology
268
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~139 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Dexamethasone injection (steroid) 910 $0 $2
Injection, diphenhydramine hcl, up to 50 mg 455 $1 $5
Injection of additional new drug or substance into vein 273 $12 $60
Office visit, established patient, complex (40-54 min) 266 $133 $265
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 222 $23 $60
Office visit, established patient (20-29 min) 163 $71 $153
Infusion, normal saline solution, sterile (500 ml = 1 unit) 154 $1 $12
Drug injection, under skin or into muscle 125 $11 $81
Office visit, established patient (30-39 min) 113 $99 $210
Infusion, normal saline solution , 1000 cc 78 $2 $15
New patient office visit, complex (60-74 min) 18 $160 $474
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
16.3% high complexity
63.5% medium
20.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$9,560
Total received (2018-2024)
Avg $1,366/year across 7 years
Top 32% in TX for hematology & oncology
48
Companies
306
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,481 (57.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,698 (38.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$381 (4.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$694
2023
$344
2022
$36
2021
$74
2020
$375
2019
$2,459
2018
$5,578

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$3,923
Novartis Pharmaceuticals Corporation
$664
PFIZER INC.
$428
Merck Sharp & Dohme Corporation
$335
E.R. Squibb & Sons, L.L.C.
$332
Boehringer Ingelheim Pharmaceuticals, Inc.
$288
Celgene Corporation
$286
Janssen Biotech, Inc.
$262
Lilly USA, LLC
$228
Ipsen Biopharmaceuticals, Inc
$222
AstraZeneca Pharmaceuticals LP
$213
SOBI, INC
$192
Bayer HealthCare Pharmaceuticals Inc.
$172
Exelixis Inc.
$145
Gilead Sciences, Inc.
$130
EMD Serono, Inc.
$122
Spectrum Pharmaceuticals Inc.
$114
GENZYME CORPORATION
$109
Rigel Pharmaceuticals, Inc.
$105
Sirtex Medical Inc
$102
Pharmacyclics LLC, An AbbVie Company
$101
Teva Pharmaceuticals USA, Inc.
$100
Genmab U.S., Inc.
$88
Amgen Inc.
$80
BIOTRONIK INC.
$71
Eisai Inc.
$70
PharmaEssentia USA Corporation
$63
Verastem, Inc.
$53
TESARO, Inc.
$47
Puma Biotechnology, Inc.
$46
Taiho Oncology, Inc.
$44
Astellas Pharma US Inc
$42
Takeda Pharmaceuticals U.S.A., Inc.
$42
Otsuka America Pharmaceutical, Inc.
$32
Merck Sharp & Dohme LLC
$31
Dendreon Pharmaceuticals LLC
$28
EISAI INC.
$28
TAIHO ONCOLOGY, INC.
$26
R-Pharm US LLC
$26
Incyte Corporation
$24
Daiichi Sankyo Inc.
$24
GlaxoSmithKline, LLC.
$20
Abbott Laboratories
$20
Mylan Institutional Inc.
$19
Seagen Inc.
$18
Amneal Pharmaceuticals LLC
$16
BOSTON SCIENTIFIC CORPORATION
$16
Seattle Genetics, Inc.
$12
Top 3 companies account for 52.5% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AVASTIN · Alecensa · Avastin · BENDEKA · BESREMI · BOSULIF · Bavencio · Baylis Medical Company Radiofrequency Puncture Generator · CALQUENCE · CONFIRM RX · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · ELIQUIS · ELITEK · EMEND · EMPLICITI · ERBITUX · Enhertu · Epkinly · Erleada · Folotyn · Fulphila · GAZYVA · GILOTRIF · GLEEVEC · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INQOVI · Imbruvica · Ixempra · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · LONSURF · LYNPARZA · Lenvima · Lonsurf · MYLOTARG · NINLARO · Nerlynx · Nexavar · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · PADCEV · PIQRAY · PROMACTA · PROVENGE · Pomalyst · REBLOZYL · ROLVEDON · RYDAPT · Revlimid · Rezlidhia · Rituxan · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNAGIS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · Tavalisse · Tazverik · VERZENIO · VONJO · VOTRIENT · Vitrakvi · XALKORI · XTANDI · Xofigo · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (57%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $344 per 100 Medicare services performed
Looking for a hematology & oncology specialist in Houston?
Compare hematology & oncology specialists in the Houston area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
191
Per 100K population
4.0
County median income
$73,104
Nearest hospital
HCA HOUSTON HEALTHCARE SOUTHEAST
2.3 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Haq is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Haq experienced with dexamethasone injection (steroid)?
Based on Medicare claims data, Dr. Haq performed 910 dexamethasone injection (steroid) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Haq receive payments from pharmaceutical companies?
Yes. Dr. Haq received a total of $9,560 from 48 companies across 306 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Haq's costs compare to other hematology & oncology specialists in Houston?
Dr. Haq's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Haq) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →